The invention discloses a rhodanine chiral cyclohexane spirocompound as shown in formula I or a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. In the formula, R1 and R2 are selected from aryl or substituted aryl respectively or simultaneously; R3 is selected from hydrogen, C1-C6 alkyl or C1-C6 alkoxyl; and R4 is selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxyl, aryl or substituted aryl. The new compound as shown in formula I, disclosed by the invention, has an inhibition effect for one or more of colon bacillus, stenotrophomonas maltophilia, acinetobacter lwoffi, staphylococcus aureus and staphylococcus epidermidis, thereby providing a new choice for clinical screening of antibacterial, bacteriostatic, bactericidal medicaments.